Related Experiment Video

Updated: Mar 30, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma

Jun Wang1, Jianbo Wen, Rui Yi

  • 1Department of Urology, Jiangxi Pingxiang People's Hospital, Jiangxi 337055, P.R. China.

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|November 6, 2015
PubMed
Abstract

Insights

This study identifies AZD6482 as a selective targeted therapy for clear cell renal cell carcinoma (ccRCC) with SETD2 mutations. AZD6482 shows promise in inhibiting ccRCC cell growth and invasiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Clear cell renal cell carcinoma (ccRCC) frequently exhibits SETD2 gene mutations.
  • Targeted therapies are crucial for improving outcomes in ccRCC.

Purpose of the Study:

  • To explore targeted therapy options for ccRCC with SETD2 mutations.
  • To identify selective inhibitors for ccRCC harboring SETD2 mutations.

Main Methods:

  • Bioinformatic analysis of GDSC and TCGA databases.
  • Identification of PI3Kβ inhibitors, specifically AZD6482.
  • Western blotting and cell-based assays to evaluate AZD6482 efficacy.

Main Results:

  • AZD6482 identified as a selective inhibitor for ccRCC with SETD2 mutations, also targeting PIK3CA and CDK6.
  • AZD6482 inhibited migration, invasiveness, and colony formation of ccRCC cells.
  • Increased PMS2 level observed with AZD6482 treatment, suggesting a role in PI3K/AKT/PMS2 pathway.

Conclusions:

  • AZD6482 is a novel, selective inhibitor for SETD2-mutated ccRCC.
  • The PI3K/AKT/PMS2 pathway may be implicated in the therapeutic response of SETD2-mutated ccRCC.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K